* Collegium Pharmaceutical Inc COLL.OQ COLL.O is
expected
to show a rise in quarterly revenue when it reports results on
August 3.
* The Stoughton Massachusetts-based company is expected to
report
a 12.0% increase in revenue to $138.401 million from $123.55
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Collegium
Pharmaceutical
Inc is for earnings of 29 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Collegium
Pharmaceutical Inc is $34, above its last closing price
of $22.77.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.26 0.31 -0.51 Missed -262.4
Dec. 31 2023 -0.04 -0.14 -0.21 Missed -44.8
Sep. 30 2022 -0.19 -0.13 0.01 Beat 107.4
Jun. 30 2022 1.38 1.42 0.32 Missed -77.5
Mar. 0.90 0.90 0.44 Missed -50.9
31 2022
Dec. 31 2021 1.06 1.04 -0.51 Missed -149.2
Sep. 30 2021 0.95 0.95 0.22 Missed -76.9
Jun. 30 2021 0.36 0.47 0.27 Missed -42.8
This summary was machine generated August 2 at 02:08 GMT. All
figures in US dollars unless otherwise stated